CF Foundation Provides $2.2 Million Award for Continued Development of ARIKACETM
June 25, 2009
The Foundation announced today it has provided a $2.2 million award to Transave, Inc. for the continued development of ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that aims to treat Pseudomonas lung infections in cystic fibrosis patients. The award will be used to support an ongoing Phase II clinical trial in CF patients with Pseudomonas lung infections and a preclinical study.
“We have followed and supported Transave’s work in this area from the beginning, and we are excited to play a role in potentially bringing another new treatment option to CF patients,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “The potential for ARIKACE is encouraging, both in terms of possible lung function improvements and quality of life outcomes.”
Transave has completed enrollment for its second CF Phase II clinical trial; results are expected to be available in July. The first CF Phase II trial, completed in June 2008, achieved positive results.
Under the terms of the agreement, Transave stands to receive $2.2 million upon achievement of certain milestones. Cystic Fibrosis Foundation Therapeutics, the nonprofit affiliate of the CF Foundation, provided a previous award of $1.7 million to support the development of ARIKACE.
Click here to read the whole press release.
| 
